Özet, AhmetDane, FaysalAykan, Nuri FarukYalçın, ŞuayibEvrensel, TürkkanÖzkan, MetinKarabulut, BülentÖrmeci, Merve NurAtasev, OzanVidot, Loick2022-09-152022-09-152022Ozet, A., Dane, F., Aykan, N. F., Yalcin, S., Evrensel, T., Ozkan, M., Karabulut, Bu., Ormeci, M. N., Atasev, O., Vidot, L. (2022). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncology.1479-6694doi. org/10.2217/fon-2022-0455https://hdl.handle.net/20.500.12713/3141Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.eninfo:eu-repo/semantics/openAccessMetastatic Colorectal CancerPRECONNECT StudyReal-World DataTrifluridine/TipiracilTurkish PopulationArticleWOS:0008475066000012-s2.0-85140272327Q310.2217/fon-2022-0455Q1